CCO Neil Aubuchon buys 4,475 shares of VKTX at $33.50; first position, stock -17.6% from 52-week high.
Neil Aubuchon, Chief Commercial Officer, initiated a first position in Viking Therapeutics by purchasing 4,475 shares at $33.50 on 2026-03-10, with no prior holdings. The company posted a net income of $-90,787,000.00 and $0.00 quarterly revenue, indicating it remains in development or early commercialization phase. The stock is currently trading at $34.66, modestly above the purchase price, and sits 17.6% below its 52-week high of $42.09 after a -7.6% decline over the past 90 days. This buy by the Chief Commercial Officer—a role typically focused on sales, market access, and revenue generation—is noteworthy given the company's lack of demonstrated revenue and large operating losses, suggesting either confidence in near-term commercialization or alignment incentive rather than a response to price weakness.